ABBV vs. PM: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ABBV and PM, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | ABBV | PM |
|---|---|---|
| Company Name | AbbVie Inc. | Philip Morris International Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Consumer Staples |
| GICS Industry | Biotechnology | Tobacco |
| Market Capitalization | 369.48 billion USD | 269.06 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | January 2, 2013 | March 17, 2008 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of ABBV and PM by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | ABBV | PM |
|---|---|---|
| 5-Day Price Return | 2.18% | 4.59% |
| 13-Week Price Return | 12.62% | -0.18% |
| 26-Week Price Return | 8.12% | 15.87% |
| 52-Week Price Return | 6.24% | 45.93% |
| Month-to-Date Return | 10.65% | 5.36% |
| Year-to-Date Return | 17.70% | 43.62% |
| 10-Day Avg. Volume | 4.64M | 4.34M |
| 3-Month Avg. Volume | 6.39M | 5.80M |
| 3-Month Volatility | 19.56% | 25.38% |
| Beta | 0.49 | 0.50 |
Profitability
Return on Equity (TTM)
ABBV
95.59%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
ABBV’s Return on Equity of 95.59% is exceptionally high, placing it well beyond the typical range for the Biotechnology industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
PM
575.44%
Tobacco Industry
- Max
- 49.48%
- Q3
- 49.48%
- Median
- 7.92%
- Q1
- 5.28%
- Min
- 4.04%
PM’s Return on Equity of 575.44% is exceptionally high, placing it well beyond the typical range for the Tobacco industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
ABBV
6.45%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
ABBV’s Net Profit Margin of 6.45% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
PM
21.08%
Tobacco Industry
- Max
- 21.36%
- Q3
- 18.49%
- Median
- 11.05%
- Q1
- 6.80%
- Min
- 5.37%
A Net Profit Margin of 21.08% places PM in the upper quartile for the Tobacco industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
ABBV
18.80%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
ABBV’s Operating Profit Margin of 18.80% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.
PM
36.28%
Tobacco Industry
- Max
- 14.35%
- Q3
- 12.68%
- Median
- 11.00%
- Q1
- 10.58%
- Min
- 10.58%
PM’s Operating Profit Margin of 36.28% is exceptionally high, placing it well above the typical range for the Tobacco industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.
Profitability at a Glance
| Symbol | ABBV | PM |
|---|---|---|
| Return on Equity (TTM) | 95.59% | 575.44% |
| Return on Assets (TTM) | 2.73% | 12.56% |
| Net Profit Margin (TTM) | 6.45% | 21.08% |
| Operating Profit Margin (TTM) | 18.80% | 36.28% |
| Gross Profit Margin (TTM) | 70.93% | 66.46% |
Financial Strength
Current Ratio (MRQ)
ABBV
0.74
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
ABBV’s Current Ratio of 0.74 is notably low, falling beneath the typical range for the Biotechnology industry. This suggests a heightened liquidity risk and could indicate potential challenges in meeting its short-term obligations.
PM
0.83
Tobacco Industry
- Max
- 3.20
- Q3
- 1.83
- Median
- 0.83
- Q1
- 0.72
- Min
- 0.57
PM’s Current Ratio of 0.83 aligns with the median group of the Tobacco industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
ABBV
49.22
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
With a Debt-to-Equity Ratio of 49.22, ABBV operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
PM
186.08
Tobacco Industry
- Max
- 2.19
- Q3
- 2.19
- Median
- 0.74
- Q1
- 0.26
- Min
- 0.01
With a Debt-to-Equity Ratio of 186.08, PM operates with exceptionally high leverage compared to the Tobacco industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio (TTM)
ABBV
2.70
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
ABBV’s Interest Coverage Ratio of 2.70 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
PM
11.67
Tobacco Industry
- Max
- 36.48
- Q3
- 28.54
- Median
- 7.02
- Q1
- 6.32
- Min
- -11.45
PM’s Interest Coverage Ratio of 11.67 is positioned comfortably within the norm for the Tobacco industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | ABBV | PM |
|---|---|---|
| Current Ratio (MRQ) | 0.74 | 0.83 |
| Quick Ratio (MRQ) | 0.48 | 0.83 |
| Debt-to-Equity Ratio (MRQ) | 49.22 | 186.08 |
| Interest Coverage Ratio (TTM) | 2.70 | 11.67 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
ABBV
3.11%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ABBV’s Dividend Yield of 3.11% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
PM
3.10%
Tobacco Industry
- Max
- 6.71%
- Q3
- 6.06%
- Median
- 5.48%
- Q1
- 3.91%
- Min
- 3.27%
PM’s Dividend Yield of 3.10% is below the typical range for the Tobacco industry. This indicates that shareholder returns are likely driven more by potential capital appreciation than by dividend income.
Dividend Payout Ratio (TTM)
ABBV
226.84%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 226.84%, ABBV’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
PM
70.92%
Tobacco Industry
- Max
- 77.64%
- Q3
- 76.55%
- Median
- 50.14%
- Q1
- 47.08%
- Min
- 42.39%
PM’s Dividend Payout Ratio of 70.92% is within the typical range for the Tobacco industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | ABBV | PM |
|---|---|---|
| Dividend Yield (TTM) | 3.11% | 3.10% |
| Dividend Payout Ratio (TTM) | 226.84% | 70.92% |
Valuation
Price-to-Earnings Ratio (TTM)
ABBV
96.80
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
At 96.80, ABBV’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Biotechnology industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
PM
32.70
Tobacco Industry
- Max
- 42.16
- Q3
- 36.45
- Median
- 20.93
- Q1
- 10.52
- Min
- 9.15
PM’s P/E Ratio of 32.70 is within the middle range for the Tobacco industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
ABBV
6.24
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
ABBV’s P/S Ratio of 6.24 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
PM
6.89
Tobacco Industry
- Max
- 10.48
- Q3
- 5.39
- Median
- 3.32
- Q1
- 1.54
- Min
- 0.59
PM’s P/S Ratio of 6.89 is in the upper echelon for the Tobacco industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
ABBV
261.01
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
At 261.01, ABBV’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
PM
1,368.86
Tobacco Industry
- Max
- 4.76
- Q3
- 4.76
- Median
- 2.18
- Q1
- 1.70
- Min
- 1.06
At 1,368.86, PM’s P/B Ratio is at an extreme premium to the Tobacco industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | ABBV | PM |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 96.80 | 32.70 |
| Price-to-Sales Ratio (TTM) | 6.24 | 6.89 |
| Price-to-Book Ratio (MRQ) | 261.01 | 1,368.86 |
| Price-to-Free Cash Flow Ratio (TTM) | 19.97 | 27.63 |